Boston Scientific Corp (BSX)vsInogen Inc (INGN)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
INGN
Inogen Inc
$6.42
+1.58%
HEALTHCARE · Cap: $166.12M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 5657% more annual revenue ($20.07B vs $348.67M). BSX leads profitability with a 14.4% profit margin vs -6.5%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
INGN
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Intrinsic value data unavailable for INGN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Reasonable price relative to book value
Earnings expanding 87.3% YoY
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
2.0% revenue growth
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -12.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : INGN
The strongest argument for INGN centers on Price/Book, EPS Growth, Debt/Equity.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : INGN
The primary concerns for INGN are Revenue Growth, Market Cap, PEG Ratio.
Key Dynamics to Monitor
BSX profiles as a growth stock while INGN is a turnaround play — different risk/reward profiles.
INGN carries more volatility with a beta of 1.78 — expect wider price swings.
BSX is growing revenue faster at 15.9% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 49/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Inogen Inc
HEALTHCARE · MEDICAL DEVICES · USA
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other physicians, and third-party payers in the United States and internationally. The company is headquartered in Goleta, California.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?